OTCMKTS:SLNCF Silence Therapeutics (SLNCF) Stock Price, News & Analysis $6.53 0.00 (0.00%) As of 11/13/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartFDA EventsFinancialsNews and TrendsSEC Filings About Silence Therapeutics Stock (OTCMKTS:SLNCF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Silence Therapeutics alerts:Sign Up Key Stats Today's Range$6.53▼$6.5350-Day Range$3.85▼$6.5352-Week Range$1.06▼$6.53VolumeN/AAverage Volume10,101 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Silence Therapeutics plc is a clinical-stage biotechnology company focused on developing medicines that use RNA interference (RNAi) to selectively reduce the production of disease-associated proteins. The company’s approach is designed to target messenger RNA before it is translated into proteins, potentially addressing conditions that are difficult to treat with conventional therapies. Silence Therapeutics develops small interfering RNA (siRNA) medicines using its proprietary GalNAc-conjugated delivery technology and related RNAi platforms. Its investigational pipeline has included zerlasiran (formerly SLN360), which is designed to reduce lipoprotein(a), a genetically determined risk factor associated with cardiovascular disease, and divesiran (formerly SLN124), an RNAi therapy being studied for hematologic disorders involving excessive red blood cell production. These programs remain investigational and are not approved medicines. Founded in the United Kingdom and headquartered in London, Silence Therapeutics has historically advanced its programs through internal research, clinical development and collaborations with pharmaceutical companies. Its development activities and clinical studies have been conducted across multiple international markets. Craig Tooman has served as the company’s chief executive officer. As a biotechnology company, Silence Therapeutics’ future depends on clinical results, regulatory decisions and its ability to develop or partner its RNAi candidates.AI Generated. May Contain Errors. Read More Silence Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks2nd Percentile Overall ScoreSLNCF MarketRank™: 0.11118508655 of 5 starsSilence Therapeutics scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Silence Therapeutics. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Silence Therapeutics is -27.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Silence Therapeutics is -27.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares ShortedShort Interest Ratio / Days to CoverSilence Therapeutics has a short interest ratio ("days to cover") of 0.29, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Silence Therapeutics has recently decreased by 94.21%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSilence Therapeutics does not currently pay a dividend.Dividend GrowthSilence Therapeutics does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Silence Therapeutics this week, compared to 0 articles on an average week. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Silence Therapeutics insiders have not sold or bought any company stock.Percentage Held by Institutions7.88% of the stock of Silence Therapeutics is held by institutions.Read more about Silence Therapeutics' insider trading history. Receive SLNCF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Silence Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SLNCF Stock News HeadlinesSilence Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 14 at 7:49 AM | marketscreener.comMIs Silence Therapeutics (NasdaqGM:SLN) Reasonable Near Its $20 Deal Price?October 20, 2026 | uk.finance.yahoo.comI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 17 at 1:00 AM | Behind the Markets (Ad)Merck to Buy Silence Therapeutics for $1.3 Billion in RNA Drug PushOctober 19, 2026 | pymnts.comMerck KGaA to Spend $1.3bn on Silence TherapeuticsOctober 19, 2026 | marketscreener.comMGermany’s Merck to Buy U.K. Biotech Silence Therapeutics for $1.3 BillionOctober 19, 2026 | msn.comSilence Therapeutics agrees to $1.3 billion Merck KGaA acquisition at 130% premiumOctober 19, 2026 | msn.comAnalysts Offer Insights on Healthcare Companies: Silence Therapeutics (SLN) and ProQR (PRQR)September 11, 2026 | theglobeandmail.comSee More Headlines SLNCF Stock Analysis - Frequently Asked Questions How have SLNCF shares performed this year? Silence Therapeutics' stock was trading at $2.00 on January 1st, 2026. Since then, SLNCF shares have increased by 226.3% and is now trading at $6.5265. How do I buy shares of Silence Therapeutics? Shares of SLNCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:SLNCF CIK1479615 Webwww.silence-therapeutics.com Phone442034576900FaxN/AEmployees100Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (OTCMKTS:SLNCF) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypass...Porter & Company | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washing...Paradigm Press | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silence Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Silence Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.